MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available

Manuel Menéndez-González1, Alfonso López-Muñiz2, José A Vega3

  • 1Unidad de Neurología, Hospital Álvarez-Buylla Mieres, Spain ; Departamento de Morfología y Biología Celular, Universidad de Oviedo Oviedo, Spain ; Instituto de Neurociencias, Universidad de Oviedo Oviedo, Spain.

Abstract

Insights

A new, simple method measures medial temporal lobe atrophy (MTA) using MRI ratios for Alzheimer's disease (AD) diagnosis. This Medial Temporal Atrophy index (MTAi) offers an objective tool for clinical practice.

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiology

Background:

  • Medial temporal lobe atrophy (MTA) correlates strongly with Alzheimer's disease (AD) pathology severity.
  • Current MTA measurement methods (volumetric or visual) are complex or subjective, hindering routine clinical use.
  • A need exists for a simple, objective method to assess MTA in clinical practice for AD diagnosis.

Purpose of the Study:

  • To introduce a novel, straightforward, and objective method for quantifying MTA relative to global atrophy.
  • To describe the rationale and methodology of this new neuroimaging approach.

Main Methods:

  • A 2D ratio, the Medial Temporal Atrophy index (MTAi), is calculated from a single coronal MRI slice.
  • The method involves manually tracing three regions: the medial temporal lobe (MTL), the hippocampal/parahippocampal parenchyma within the MTL, and the ipsilateral lateral ventricle.
  • The formula MTAi = (A - B)× 10/C quantifies relative MTL atrophy.

Main Results:

  • The described method provides a simple 2D measurement of relative MTA.
  • The Medial Temporal Atrophy index (MTAi) is objective and utilizes readily available neuroimaging.

Conclusions:

  • The MTAi offers a simple, objective 2D method for assessing relative medial temporal lobe atrophy.
  • This index has the potential to aid in the accurate diagnosis of AD within routine clinical settings.
  • Further research is warranted to validate MTAi for early AD diagnosis, tracking disease progression, and differential diagnosis.

Related Concept Videos